Dr. Evangelos Terpos on the APOLLO Study 

Background of the study:

APOLLO  is a phase III trial of pomalidomide and dexamethasone (Pd) ± subcutaneous daratumumab (1800 mg, co-formulated with recombinant human hyaluronidase PH20 in 15 mL) in patients with relapsed/refractory multiple myeloma (RRMM) and ≥1 prior line of therapy including lenalidomide and a proteasome inhibitor. After 16.9 months (mo) median follow-up, D-Pd significantly reduced the rate of progression or death by 37% relative to Pd. Patients with RRMM have reduced health-related quality of life (HRQoL) compared with age- and sex-matched populations. Here, we present patient-reported outcomes (PROs) from the APOLLO trial.

In this video:

Dr. Evangelos Terpos (National and Kapodistrian University of Athens, Athens, Greece) presents the results patient reported outcomes in the APOLLO study.

Conclusions:

When daratumumab was added to Pd, patients did not experience any decrements in HRQoL while on treatment, but some patients experienced reductions in pain as well as clinically meaningful improvements in symptoms and emotional/physical function. These findings complement the clinical benefits of D-Pd in RRMM patients and further support its use in this RRMM population. 

Clinical trial information: NCT03180736